MA
RCKT icon

Minerva Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Minerva Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-16,190
Closed -$120K – 75
2017
Q2 		$120K Hold
16,190
– – 0.07% 68
2017
Q1 		$126K Buy
+16,190
New +$109K 0.07% 68

Other funds holding RCKT

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Minerva Advisors's RCKT Position: Q3 2017 in Review

Minerva Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q3 2017, closing a stake of 16,190 shares — an estimated $120K sold.

Minerva Advisors first reported a position in RCKT in Q1 2017 and held it in 2 quarters. The position peaked at $126K in Q1 2017. 35 funds tracked by Wall St. Rank hold RCKT as of Q3 2017.

  • Minerva Advisors reported no remaining Rocket Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Minerva Advisors sold 16,190 Rocket Pharmaceuticals shares in Q3 2017, an estimated $120K.
  • Minerva Advisors first reported a position in Rocket Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Minerva Advisors's Rocket Pharmaceuticals position peaked at $126K in Q1 2017.
  • 35 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2017.

Based on Minerva Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.